[et_pb_section fb_built=”1″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.8″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Calgary, Alberta\u2013(Newsfile Corp. \u2013 February 15, 2022) \u2013\u00a0Marvel Biosciences Corp. (TSXV: MRVL)\u00a0<\/b>and its wholly-owned subsidiary, Marvel Biotechnology Inc.\u00a0<\/b>(collectively the\u00a0<\/b>\u201cCompany<\/b>\u201c\u00a0<\/b>or\u00a0<\/b>\u201cMarvel<\/b>\u201c), is pleased to report the proxy tabulation (\u201cTabulation<\/b>\u201c) from Odyssey Trust Company in connection with its Annual and Special Meeting of Shareholders held virtually on February 15, 2022 (the \u201cMeeting<\/b>\u201c), as well as results from the Meeting.<\/p>\n
The Tabulation is the final sum of the voting results of the Meeting and is the result of all the properly submitted proxies by shareholders in advance of the proxy cut-off time.<\/p>\n
The Tabulation results are as follows:<\/p>\n
| MOTIONS<\/b><\/td>\n | NUMBER OF SHARES<\/b><\/td>\n | PERCENTAGE OF VOTES CAST<\/b><\/td>\n<\/tr>\n| \u00a0<\/td>\n | FOR<\/b><\/td>\n | AGAINST<\/b><\/td>\n | WITHHELD\/ABSTAIN<\/b><\/td>\n | RESTRICTED<\/b><\/td>\n | SPOILED<\/b><\/td>\n | NON VOTE<\/b><\/td>\n | FOR<\/b><\/td>\n | AGAINST<\/b><\/td>\n | WITHHELD\/ABSTAIN<\/b><\/td>\n<\/tr>\n | Number of Directors<\/td>\n | 13,668.375<\/td>\n | 0.00<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 100.00<\/td>\n | 0<\/td>\n | 0.00<\/td>\n<\/tr>\n | J. Roderick Matheson<\/td>\n | 12,941,542<\/td>\n | 0.00<\/td>\n | 726,833<\/td>\n | \u00a0<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 94.68<\/td>\n | 0<\/td>\n | 5.32<\/td>\n<\/tr>\n | Mark Williams<\/td>\n | 13,668,375<\/td>\n | 0.00<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 100.00<\/td>\n | 0<\/td>\n | 0.00<\/td>\n<\/tr>\n | Neil A. Johnson<\/td>\n | 13,667,375<\/td>\n | 0.00<\/td>\n | 1,000<\/td>\n | \u00a0<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 99.99<\/td>\n | 0<\/td>\n | 0.01<\/td>\n<\/tr>\n | Jeremy Fehr<\/td>\n | 12,941,542<\/td>\n | 0.00<\/td>\n | 726,833<\/td>\n | \u00a0<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 94.68<\/td>\n | 0<\/td>\n | 5.32<\/td>\n<\/tr>\n | Appointment of Auditors<\/td>\n | 13,668,375<\/td>\n | 0.00<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 100.00<\/td>\n | 0<\/td>\n | 0.00<\/td>\n<\/tr>\n | Adoption of New Form of Stock Option Plan<\/td>\n | 4,787,933<\/td>\n | 790,333<\/td>\n | 0.00<\/td>\n | 8,090,049<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 85.83<\/td>\n | 14.17<\/td>\n | 0.00<\/td>\n<\/tr>\n | Ratification of Option Grants to Directors and Officers<\/td>\n | 5,207,993<\/td>\n | 790,333<\/td>\n | 0.00<\/td>\n | 7,670,049<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 86.82<\/td>\n | 13.18<\/td>\n | 0.00<\/td>\n<\/tr>\n | Ratification of Option Grants to Consultants<\/td>\n | 12,458,042<\/td>\n | 790,333<\/td>\n | 0.00<\/td>\n | 420,000<\/td>\n | 0.00<\/td>\n | \u00a0<\/td>\n | 94.03<\/td>\n | 5.97<\/td>\n | 0.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n | <\/p>\n At the Meeting, holders of common shares of Marvel: (i) received the financial statements and the auditor\u2019s report for the year ended July 31, 2021; (ii) fixed the number of directors to be elected at the Meeting at four; (iii) elected J. Roderick Matheson, Mark Williams, Neil Johnson and Jeremy Fehr to the Board of Directors; (iv) re-appointed MNP LLP as Marvel\u2019s auditors; (v) approved the Company\u2019s new form of stock option plan (the \u201cPlan<\/b>\u201c); (vi) approved option grants under the Plan to the Company\u2019s directors and officers; and (vii) approved option grants under the Plan to certain of the Company\u2019s consultants.<\/p>\n Ms. Joanne Yan did not stand for re-election at the Meeting. Marvel and its Board wishes to extend its appreciation for Ms. Yan\u2019s guidance and service to the Company and its stakeholders.<\/p>\n The Company\u2019s Articles allow the directors, between annual general meetings, to appoint one or more additional directors of the Company to serve until the next annual general meeting but the number of additional directors shall not at any time exceed one-third of the number of directors who held office at the expiration of the last annual meeting.<\/p>\n Pursuant to the Company\u2019s Articles, immediately subsequent to the Meeting, the directors appointed S. Randall Smallbone as an additional director of the Company. Mr. Smallbone is the President, CEO and a Director of Astron Connect Inc. In addition, Mr. Smallbone is the Chair of the Board of Directors of both The Burlington Economic Development Corporation and Joseph Brant Hospital. He is also a Board member of Entourage Health Corp., Hanwei Energy Services Corp. and on the Advisory Board of Pneu-Hyd Industries Inc.<\/p>\n Mr. Smallbone has been the CFO of three Public Companies, Migao Corporation, KCP Income Fund and Decoma International Inc (Magna International Inc.). He was also on the Board of Norcast Income Fund and numerous other private and NFP Boards.<\/p>\n Following Mr. Smallbone\u2019s appointment to the Board, the directors of the Company are as follows: J. Roderick Matheson, Jeremy Fehr, Neil A. Johnson, S. Randall Smallbone and Mark Williams.<\/p>\n Following the Meeting the Board re-appointed the Company\u2019s officers as follows:<\/p>\n J. Roderick Matheson \u2013 Chairman of the Board and Chief Executive Officer Subsequent to Mr. Smallbone\u2019s appointment to the Board, the directors reconstituted the Board of Directors\u2019 committees as follows:<\/p>\n Audit Committee<\/b><\/u> Corporate Governance & The Company also wishes to announce that, effective February 15, 2022, the directors have appointed Ms. Joanne Yan as a member of the Company\u2019s Advisory Board.<\/p>\n Further disclosure on the matters approved at the Meeting can be found in the Management Information Circular dated January 6, 2022 and filed on SEDAR on January 20, 2022.<\/p>\n Contact Information Investor Relations:<\/b> |